Browse press releases
The newest releases come first, each with its full text here and a link to its original. Try the filters to narrow them down.
- Keynova GroupHome Lenders Enhance Digital Impact with Accelerated Closing and Funding, Relationship Value-Adds and Visual Consumer-Education ContentBank of America and PNC Remain Tied for the Lead in Keynova Group's 2026 Mortgage-Home Equity Scorecard — Keynova Group, the leading competitive intelligence source for digital financial services, today announced the results of its 2026...
- MetaLaunching ‘Meta Startup School’ to Accelerate Growth For Early-Stage StartupsCompanies: Meta PlatformsWe are launching Meta Startup School, a three-month programme designed to help early-stage consumer brands accelerate growth. The first cohort will see 200 startups get exclusive access to support and training from venture capital firms and industry experts. The post Launching ‘Meta Startup School’ to Accelerate Growth For Early-Stage Startups appeared first on Meta Newsroom.
- Samsung[Video] Samsung AI Assistant Helps Teachers Create More Engaging and Accessible LessonsCompanies: Samsung ElectronicsHelping every student stay engaged and supported throughout a lesson requires teachers to balance instruction, interaction, and individual learning needs. Managing these different needs while maintaining lesson flow can add to a teacher’s workload. Samsung AI Assistant is a built-in app for compatible Android-based Samsung Interactive Displays that helps teachers support every stage of a […]
- Onchain Foundation Becomes Strategic Shareholder of Trust Square Ecosystem AG to Accelerate Global Innovation PlatformZURICH, SWITZERLAND, Aug 19, 2026 - Trust Square Ecosystem AG today announced that the Onchain Foundation has become a strategic shareholder of the company through a strategic investment, marking a significant milestone in Trust Square's transformation into a global ecosystem platform for emerging technologies. The investment from the Onchain Foundation will support the international scaling of Trust Square's ecosystem-driven business model, including the expansion of its flagship initiatives, Trust Forum, Trust Circle, and Trust Hive, as well as further ecosystem development activities connecting global innovators, entrepreneurs, investors, corporates, policymakers, and academia. As part of the broader strategic expansion of Trust Square's shareholder ecosystem, Inacta Ventures has also become a strategic shareholder of Trust Square Ecosystem AG, further strengthening the company's foundation with additional expertise in venture building and ecosystem development. This expansion builds upon the existing strategic partnership with The Hashgraph Association, which is a shareholder and ecosystem partner of Trust Square. Scaling Trust Square's Global Innovation Platform The global innovation landscape is evolving at unprecedented speed. Artificial intelligence, Web3, blockchain infrastructure, and other frontier technologies are reshaping industries, economies, societies, and governance. However, meaningful innovation requires more than technology alone. It requires trusted environments where leaders can exchange ideas openly, build relationships, and collaborate on solutions that create long-term impact. With the strategic investment from the Onchain Foundation, Trust Square will accelerate the international expansion of its ecosystem-driven business model, scaling its flagship initiatives across leading innovation hubs worldwide. At the core of this expansion are three complementary formats designed to create meaningful connections, foster collaboration, and support the responsible adoption of emerging technologies. Trust Forum The Trust Forum is Trust Square's biannual flagship gathering, bringing together up to 250 global leaders for confidential dialogue, strategic exchange, and collaboration on emerging technologies and future opportunities. Trust Circle The Trust Circle is a global network of curated gatherings connecting 80 to 100 innovators, entrepreneurs, investors, corporates, policymakers, and academics through meaningful discussions and knowledge exchange. Trust Hive The Trust Hive consists of agile, invitation-only pop-up gatherings that activate the ecosystem around timely topics, opportunities, and special occasions. Together, Trust Forum, Trust Circle, and Trust Hive create a global platform for trusted dialogue, ecosystem development, and collaboration among leaders shaping the future of technology. Strengthening the Trust Square Ecosystem The partnership with the Onchain Foundation reflects a shared commitment to advancing innovation through collaboration, ecosystem development, and trusted networks. The Onchain Foundation is a Swiss non-profit organization committed to advancing blockchain technology and supporting initiatives that unlock the transformative potential of decentralized systems. Through strategic partnerships, ecosystem development, and innovation programs, the Foundation works to accelerate the responsible adoption of blockchain technologies. The Hashgraph Association, an existing strategic shareholder of Trust Square, is a Swiss non-profit organization driving the global adoption of Hedera-powered solutions by funding innovation, providing training and education programs, and supporting venture initiatives. Inacta Ventures, a newly added strategic shareholder of Trust Square, is a venture builder and ecosystem architect supporting startups, corporates, and governments in adopting emerging technologies. With a presence in Switzerland and the UAE, Inacta Ventures supports more than 100 startups and corporates. Together, these organizations strengthen Trust Square's ability to connect technology leaders, founders, investors, enterprises, institutions, and communities across global innovation ecosystems. Leadership Expansion As part of the strategic partnership, Guido Schmitz-Krummacher, Managing Director of the Onchain Foundation, has joined the Board of Directors of Trust Square Ecosystem AG. His appointment further strengthens Trust Square's strategic leadership and reflects the close alignment between both organizations' missions to foster innovation, collaboration, and responsible technology adoption. Executive Quotes Kamal Youssefi, President of the Board of Directors of Trust Square Ecosystem AG and President of the Board of Directors of The Hashgraph Association: "We're proud of the growth and recognition Trust Square has achieved over the years. We've always been convinced that a vibrant Web3 ecosystem cannot be built on technology alone but rather emerges through strategic partnerships and cross-chain collaborations. With the Onchain Foundation joining The Hashgraph Association and Inacta Ventures becoming a strategic shareholder of Trust Square, we are confident that Trust Square's global network of Web3 leaders, entrepreneurs, and policymakers will drive innovation, enhance cross-chain collaboration, foster the deployment of viable decentralized solutions, and support the mainstream adoption of the Web3 industry." Guido Schmitz-Krummacher, Managing Director of the Onchain Foundation, Managing Director and Member of the Board of Onchain Ventures AG, Director of Lisk Ltd., and Member of the Board of Trust Square Ecosystem AG: "Our blockchain ecosystem is facing significant challenges, while the AI ecosystem is moving beyond the initial hype cycle and entering a necessary phase of consolidation around its core values. This makes it more important than ever to bring together the innovation leaders of both ecosystems at meetings and events where the future of blockchain and AI can be discussed, shaped, and advanced collaboratively. Trust Square and its team are well positioned to play a leading role in addressing these challenges. As an entrepreneur and an 'old blockchain guy,' I am excited to contribute to this mission." About Trust Square Ecosystem AG Trust Square Ecosystem AG is a Swiss ecosystem builder connecting innovators, entrepreneurs, investors, policymakers, academics, and industry leaders shaping the future of technology. Through its flagship initiatives, Trust Forum, Trust Circle, Trust Hive, and additional ecosystem development activities, Trust Square creates trusted environments where meaningful collaboration drives innovation across AI, Web3, digital assets, digital identity, cybersecurity, sustainability, and other frontier technologies. About the Onchain Foundation The Onchain Foundation is a Swiss non-profit organization committed to advancing blockchain technology and supporting initiatives that unlock the transformative potential of decentralized systems. Through strategic partnerships, ecosystem development, education, and innovation programs, the Foundation works to accelerate the responsible adoption of blockchain technologies and foster collaboration across the global technology ecosystem. About The Hashgraph Association The Hashgraph Association is a Swiss non-profit organization that drives the global adoption of Hedera-powered solutions by funding innovation, providing training and education programs, and supporting venture initiatives. Through its ecosystem programs, The Hashgraph Association supports organizations, developers, enterprises, and entrepreneurs building the next generation of decentralized applications and digital infrastructure. About Inacta Ventures Inacta Ventures is a venture builder and ecosystem architect supporting startups, corporates, and governments in adopting emerging technologies. With a presence in Switzerland and the UAE, Inacta Ventures builds ecosystems and ventures that accelerate innovation and enterprise adoption, supporting more than 100 startups and corporates. Media Contact: Fabio Schlaf Head of Ecosystem Development Trust Square Ecosystem AG [email protected]
- Think AcademyThink Academy Introduces Class+, Reimagining Mathematics Learning Through Exploration and GrowthThink Academy, a global K–12 mathematics education provider, is exploring a new approach to mathematics learning through Class+, an innovative classroom experience being piloted across selected learning centers in multiple markets. By...
- Cardinal Point Wealth Management, ULC TorontoCardinal Point Explains RESP Withdrawal Rules for Canada–U.S. FamiliesNew article outlines how residency, withdrawal sequencing, and differing Canadian and U.S. tax rules can affect education savings
- Everest Medicines Reports 1H 2026 Results, Enters New Phase as Growth Accelerates and Innovation Gains MomentumEverest Medicines (01952.HK) announced its interim results for the six months ended June 30, 2026. Everest delivered strong growth and reached an important profitability milestone in the first half of 2026. Total revenue increased 157% year-on-year to RMB 1.148 billion, driven by continued commercial momentum across the company’s portfolio. Gross margin excluding non-cash items reached 73.7%, while operating expenses as a percentage of revenue decreased by 64.0 percentage points year-on-year, reflecting increasing operating leverage and execution efficiency. From the first-half results, the company’s growth drivers are broadening beyond the commercialization of core products to include portfolio expansion, monetization of innovative assets, and global expansion. In the first half of 2026, the company achieved non-IFRS net profit of RMB 97.23 million, while IFRS net loss narrowed by 98% year-on-year. Everest ended the period with RMB 1.859 billion in cash. Following the reporting period, the company received approximately RMB 770 million in July from the upfront payment under its global licensing and collaboration agreement for civorebrutinib, further strengthening its financial position and capacity to invest in future growth. Mr. Yifang Wu, Chairman of the Board of Everest Medicines, said: “Everest Medicines has entered a new phase of development as an innovation-driven, integrated biopharmaceutical company. Guided by our 2030 Strategy, we are strengthening our capabilities in innovation, commercialization, and global development, accelerating the realization of global value and laying a stronger foundation for sustainable, high-quality growth.” During the period, the company achieved profitability, while expanding its innovative pipeline and advancing its R&D programs. Through continued efforts to strengthen its BD capabilities, the company is developing a model that combines in-licensed and internally developed early-stage assets, exemplified by civorebrutinib (also known as EVER001), with internal incubation and development creating opportunities to out-license innovative assets and realize their value. At the same time, the company is bringing in high-quality mid- to late-stage assets, exemplified by NEFECON(R), while continuing to build its commercialization capabilities and generate further opportunities for BD partnerships. These efforts are enhancing the efficiency of innovation resource allocation and accelerating the translation of innovation into clinical and commercial value. Everest’s marketed portfolio continued to gain momentum NEFECON(R) maintained strong sales momentum. In the first half of 2026, sales revenue from NEFECON(R) reached RMB 889 million, with net sales increasing 94% year-on-year. Through deeper penetration across key hospitals, broader market expansion, enhanced physician and patient education, and continued generation of real-world evidence, Everest is supporting broader adoption of treatment strategies focused on addressing underlying causes, early intervention, and long-term management. Following approval, VELSIPITY(R) moved rapidly into commercialization, with local manufacturing progressing. XERAVA(R) delivered steady hospital sales growth, while local manufacturing advanced as planned. The company also reached an understanding with Hainan Herui Pharmaceutical Co., Ltd. regarding certain NEFECON(R)-related patent matters and entered into a commercialization collaboration for budesonide enteric capsules, further broadening treatment options for patients. Meanwhile, commercialization services for Hasten Biopharmaceuticals continued to contribute to revenue growth. Services for mature products under the CSO arrangement commenced in March 2026, generating RMB 145 million in service revenue and RMB 28 million in commercialization profit in the first half of the year. Mr. Rogers Yongqing Luo, Chief Executive Officer of Everest Medicines, said: “In the first half of 2026, the company continued to execute its strategy and accelerate the translation of innovation into clinical and commercial value. Solid progress across commercialization, BD, in-house R&D, and global expansion further strengthened our foundation for sustainable growth and our ability to bring innovative therapies to patients. Our BD strategy is building a diversified portfolio of future growth drivers through global partnerships for internally developed assets and selective in-licensing of differentiated innovative assets, while our in-house R&D continues to generate clinical progress. With the establishment of a pan-Asia-Pacific commercialization platform, we are also extending our proven capabilities from China into other Asian markets.” EVER001 global licensing deal expected to accelerate overseas development In June, the company entered into an exclusive licensing and collaboration agreement with Travere Therapeutics, Inc. (NASDAQ: TVTX) for the development and commercialization of civorebrutinib (also known as EVER001) in all markets outside China and certain countries in East and Southeast Asia. The deal has a total potential value of up to $1.1425 billion, including an upfront payment of $112.5 million and up to approximately $1.03 billion in additional cash payments tied to specified clinical development, regulatory and commercial milestones across up to five indications. Travere will also pay tiered royalties on future sales in its licensed territories, ranging from high single-digit to double-digit percentages based on annual net sales thresholds. CICC believes the partnership is expected to accelerate the global clinical development and commercialization of EVER001 and could advance its development in membranous nephropathy. BOCOM International is positive on EVER001’s overseas market potential and its development opportunities across additional indications. EVER001 achieved positive 52-week Phase 1b/2a clinical results, and a Phase 2 basket trial has been initiated in China to further evaluate its potential in autoimmune kidney diseases, including FSGS, MCD, and IgAN. BD expansion further strengthens the product pipeline The company continued to selectively introduce mid- to late-stage assets with strong commercial potential. MT1013, DMX-200, and Bejescin(R) strengthened its nephrology and autoimmune portfolio; CARDAMYST(R) and Sumecigrel (formerly known as Vicagrel) further expanded its cardiovascular portfolio; and LNZ100, together with VIS-101, enhanced its ophthalmology portfolio. With multiple assets moving through key regulatory and commercialization milestones, the company is building a diversified portfolio of future growth drivers. CARDAMYST(R) is expected to receive approval in the third quarter of 2026, LEROCHOL(R) and LNZ100 are expected to receive approval in 2027, and MT1013 is expected to receive approval in 2028. In-house R&D and pan-Asia-Pacific expansion advance The company’s in-house R&D also translated into clinical progress. The company’s proprietary AI+mRNA platform also advanced, with its personalized mRNA cancer vaccine EVM16 achieving its first-in-human clinical data readout and planned to enter an investigator-initiated Phase 1b study in the fourth quarter of 2026. EVM18, the company’s in vivo CAR-T therapy, has initiated IIT studies across multiple autoimmune diseases and is advancing toward global IND filings. The acquisition of Hasten Biopharmaceuticals (SG) Pte. Ltd. further strengthened the company’s global commercialization capabilities and established a pan-Asia-Pacific commercialization platform. The platform provides a foundation for scaling the company’s proven commercialization capabilities from China across Asian markets, supporting the regional expansion of both existing and future products. Meanwhile, CBC Group and the company’s Directors have collectively purchased 5.163 million shares since December 2025, with the transactions totaling more than HK$172.5 million, demonstrating their confidence in the company’s strategic direction and long-term prospects. Overall, Everest Medicines is gradually developing a growth model built on the commercialization of core products, portfolio expansion through BD, a pipeline of innovative assets generated through in-house R&D, and international expansion through global partnerships and its pan-Asia-Pacific platform. As the company enters its new phase, the coordinated strengthening of its capabilities in innovation resource integration, commercialization, and global development is expected to provide an important foundation for future growth.
- Beyond Back-to-School, Canton Fair Helps Global Buyers Stay Ahead of Key Retail SeasonsAs the back-to-school shopping season gains momentum, demand for stationery, learning tools, and educational technology products is on the rise. As one of the most essential items in students' daily learning routines, writing instruments...
- Everest Medicines Reports 1H 2026 Results, Enters New Phase as Growth Accelerates and Innovation Gains MomentumEverest Medicines (01952.HK) announced its interim results for the six months ended June 30, 2026. Everest delivered strong growth and reached an important profitability milestone in the first half of 2026. Total revenue increased 157% year-on-year to RMB 1.148 billion, driven by continued commercial momentum across the company’s portfolio. Gross margin excluding non-cash items reached 73.7%, while operating expenses as a percentage of revenue decreased by 64.0 percentage points year-on-year, reflecting increasing operating leverage and execution efficiency. From the first-half results, the company’s growth drivers are broadening beyond the commercialization of core products to include portfolio expansion, monetization of innovative assets, and global expansion. In the first half of 2026, the company achieved non-IFRS net profit of RMB 97.23 million, while IFRS net loss narrowed by 98% year-on-year. Everest ended the period with RMB 1.859 billion in cash. Following the reporting period, the company received approximately RMB 770 million in July from the upfront payment under its global licensing and collaboration agreement for civorebrutinib, further strengthening its financial position and capacity to invest in future growth. Mr. Yifang Wu, Chairman of the Board of Everest Medicines, said: “Everest Medicines has entered a new phase of development as an innovation-driven, integrated biopharmaceutical company. Guided by our 2030 Strategy, we are strengthening our capabilities in innovation, commercialization, and global development, accelerating the realization of global value and laying a stronger foundation for sustainable, high-quality growth.” During the period, the company achieved profitability, while expanding its innovative pipeline and advancing its R&D programs. Through continued efforts to strengthen its BD capabilities, the company is developing a model that combines in-licensed and internally developed early-stage assets, exemplified by civorebrutinib (also known as EVER001), with internal incubation and development creating opportunities to out-license innovative assets and realize their value. At the same time, the company is bringing in high-quality mid- to late-stage assets, exemplified by NEFECON(R), while continuing to build its commercialization capabilities and generate further opportunities for BD partnerships. These efforts are enhancing the efficiency of innovation resource allocation and accelerating the translation of innovation into clinical and commercial value. Everest’s marketed portfolio continued to gain momentum NEFECON(R) maintained strong sales momentum. In the first half of 2026, sales revenue from NEFECON(R) reached RMB 889 million, with net sales increasing 94% year-on-year. Through deeper penetration across key hospitals, broader market expansion, enhanced physician and patient education, and continued generation of real-world evidence, Everest is supporting broader adoption of treatment strategies focused on addressing underlying causes, early intervention, and long-term management. Following approval, VELSIPITY(R) moved rapidly into commercialization, with local manufacturing progressing. XERAVA(R) delivered steady hospital sales growth, while local manufacturing advanced as planned. The company also reached an understanding with Hainan Herui Pharmaceutical Co., Ltd. regarding certain NEFECON(R)-related patent matters and entered into a commercialization collaboration for budesonide enteric capsules, further broadening treatment options for patients. Meanwhile, commercialization services for Hasten Biopharmaceuticals continued to contribute to revenue growth. Services for mature products under the CSO arrangement commenced in March 2026, generating RMB 145 million in service revenue and RMB 28 million in commercialization profit in the first half of the year. Mr. Rogers Yongqing Luo, Chief Executive Officer of Everest Medicines, said: “In the first half of 2026, the company continued to execute its strategy and accelerate the translation of innovation into clinical and commercial value. Solid progress across commercialization, BD, in-house R&D, and global expansion further strengthened our foundation for sustainable growth and our ability to bring innovative therapies to patients. Our BD strategy is building a diversified portfolio of future growth drivers through global partnerships for internally developed assets and selective in-licensing of differentiated innovative assets, while our in-house R&D continues to generate clinical progress. With the establishment of a pan-Asia-Pacific commercialization platform, we are also extending our proven capabilities from China into other Asian markets.” EVER001 global licensing deal expected to accelerate overseas development In June, the company entered into an exclusive licensing and collaboration agreement with Travere Therapeutics, Inc. (NASDAQ: TVTX) for the development and commercialization of civorebrutinib (also known as EVER001) in all markets outside China and certain countries in East and Southeast Asia. The deal has a total potential value of up to $1.1425 billion, including an upfront payment of $112.5 million and up to approximately $1.03 billion in additional cash payments tied to specified clinical development, regulatory and commercial milestones across up to five indications. Travere will also pay tiered royalties on future sales in its licensed territories, ranging from high single-digit to double-digit percentages based on annual net sales thresholds. CICC believes the partnership is expected to accelerate the global clinical development and commercialization of EVER001 and could advance its development in membranous nephropathy. BOCOM International is positive on EVER001’s overseas market potential and its development opportunities across additional indications. EVER001 achieved positive 52-week Phase 1b/2a clinical results, and a Phase 2 basket trial has been initiated in China to further evaluate its potential in autoimmune kidney diseases, including FSGS, MCD, and IgAN. BD expansion further strengthens the product pipeline The company continued to selectively introduce mid- to late-stage assets with strong commercial potential. MT1013, DMX-200, and Bejescin(R) strengthened its nephrology and autoimmune portfolio; CARDAMYST(R) and Sumecigrel (formerly known as Vicagrel) further expanded its cardiovascular portfolio; and LNZ100, together with VIS-101, enhanced its ophthalmology portfolio. With multiple assets moving through key regulatory and commercialization milestones, the company is building a diversified portfolio of future growth drivers. CARDAMYST(R) is expected to receive approval in the third quarter of 2026, LEROCHOL(R) and LNZ100 are expected to receive approval in 2027, and MT1013 is expected to receive approval in 2028. In-house R&D and pan-Asia-Pacific expansion advance The company’s in-house R&D also translated into clinical progress. The company’s proprietary AI+mRNA platform also advanced, with its personalized mRNA cancer vaccine EVM16 achieving its first-in-human clinical data readout and planned to enter an investigator-initiated Phase 1b study in the fourth quarter of 2026. EVM18, the company’s in vivo CAR-T therapy, has initiated IIT studies across multiple autoimmune diseases and is advancing toward global IND filings. The acquisition of Hasten Biopharmaceuticals (SG) Pte. Ltd. further strengthened the company’s global commercialization capabilities and established a pan-Asia-Pacific commercialization platform. The platform provides a foundation for scaling the company’s proven commercialization capabilities from China across Asian markets, supporting the regional expansion of both existing and future products. Meanwhile, CBC Group and the company’s Directors have collectively purchased 5.163 million shares since December 2025, with the transactions totaling more than HK$172.5 million, demonstrating their confidence in the company’s strategic direction and long-term prospects. Overall, Everest Medicines is gradually developing a growth model built on the commercialization of core products, portfolio expansion through BD, a pipeline of innovative assets generated through in-house R&D, and international expansion through global partnerships and its pan-Asia-Pacific platform. As the company enters its new phase, the coordinated strengthening of its capabilities in innovation resource integration, commercialization, and global development is expected to provide an important foundation for future growth.
- Aurentis Capital Group Announces Technology-Driven Trading Platform for Global MarketsLONDON, Aug 19, 2026 - Aurentis Capital Group has announced a technology-driven trading platform designed to provide market participants with access to a range of global financial instruments through a streamlined digital environment. The platform is designed around the needs of traders seeking access to markets including equities, commodities, currencies and indices. Aurentis Capital said its approach combines market access with digital tools intended to support market monitoring, analysis and account management. Platform Designed for Multi-Asset Market Access Aurentis Capital Group's platform brings multiple financial markets together within a single trading environment. The offering is intended to allow users to monitor market movements, review positions and manage trading activity through digital devices. The company said the platform has been developed with an emphasis on accessibility and ease of use, with functionality available across desktop and mobile environments. Focus on Trading Technology The platform incorporates market-monitoring and analytical functionality intended to support traders as they assess changing market conditions. Features include market data, charting capabilities and account-management tools. The company said the technology is intended to provide traders with a centralized environment for monitoring markets and managing their trading activity. Educational and Analytical Resources Alongside its trading technology, Aurentis Capital provides educational and analytical resources covering financial markets and trading-related topics. The resources are intended to support users in developing their understanding of market structure, trading strategies and risk-management principles. Educational materials may include market commentary, tutorials, analytical resources and other learning content, subject to availability through the platform. Risk and Market Considerations Trading financial instruments, particularly leveraged products such as Contracts for Difference (CFDs), involves significant risk and may not be suitable for all investors. Market prices can move rapidly, and losses can occur. Depending on the product, leverage and applicable jurisdiction, losses may exceed the initial amount invested. Prospective clients should review the applicable product documentation, terms and risk disclosures before trading and should consider whether the products are appropriate for their individual circumstances. Where appropriate, independent financial advice should be obtained. About Aurentis Capital Group Aurentis Capital (https://aurentiscg.com) is a financial-services brand focused on providing technology-enabled access to global financial markets. The company develops its offering around digital trading infrastructure, market access and resources intended to support market participants. Media contact Brand: Aurentis Capital Group Contact: Media team Website: https://aurentiscg.com
- Aurentis Capital Group Announces Technology-Driven Trading Platform for Global MarketsLONDON, Aug 19, 2026 - Aurentis Capital Group has announced a technology-driven trading platform designed to provide market participants with access to a range of global financial instruments through a streamlined digital environment. The platform is designed around the needs of traders seeking access to markets including equities, commodities, currencies and indices. Aurentis Capital said its approach combines market access with digital tools intended to support market monitoring, analysis and account management. Platform Designed for Multi-Asset Market Access Aurentis Capital Group's platform brings multiple financial markets together within a single trading environment. The offering is intended to allow users to monitor market movements, review positions and manage trading activity through digital devices. The company said the platform has been developed with an emphasis on accessibility and ease of use, with functionality available across desktop and mobile environments. Focus on Trading Technology The platform incorporates market-monitoring and analytical functionality intended to support traders as they assess changing market conditions. Features include market data, charting capabilities and account-management tools. The company said the technology is intended to provide traders with a centralized environment for monitoring markets and managing their trading activity. Educational and Analytical Resources Alongside its trading technology, Aurentis Capital provides educational and analytical resources covering financial markets and trading-related topics. The resources are intended to support users in developing their understanding of market structure, trading strategies and risk-management principles. Educational materials may include market commentary, tutorials, analytical resources and other learning content, subject to availability through the platform. Risk and Market Considerations Trading financial instruments, particularly leveraged products such as Contracts for Difference (CFDs), involves significant risk and may not be suitable for all investors. Market prices can move rapidly, and losses can occur. Depending on the product, leverage and applicable jurisdiction, losses may exceed the initial amount invested. Prospective clients should review the applicable product documentation, terms and risk disclosures before trading and should consider whether the products are appropriate for their individual circumstances. Where appropriate, independent financial advice should be obtained. About Aurentis Capital Group Aurentis Capital (https://aurentiscg.com) is a financial-services brand focused on providing technology-enabled access to global financial markets. The company develops its offering around digital trading infrastructure, market access and resources intended to support market participants. Media contact Brand: Aurentis Capital Group Contact: Media team Website: https://aurentiscg.com
- Phoenix Energy CEO Adam Ferrari Receives 2026 Young Alumni Achievement Award from University of IllinoisIRVINE, Calif., August 18, 2026--Phoenix Energy has announced that founder and Phoenix Energy CEO Adam Ferrari has been selected to receive the 2026 Young Alumni Achievement Award from the University of Illinois Urbana-Champaign Department of Chemical & Biomolecular Engineering.